Related Experiment Video
Updated: Mar 12, 2026

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
CARF activates beta-catenin/TCF signaling in the hepatocellular carcinoma
Xin Fan1, Xiaoyan Ma2, Lei Cui1
1Department of General Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, PR China.
Abstract:
Overactivation of Ras signaling is very common in the hepatocellular carcinoma (HCC) due to its constitutive active mutation, which makes it a big challenge to target Ras signaling. Therefore, identifying effectors downstream of Ras signaling would benefit the development of novel therapeutic strategies. In this study, it was found that the expression of CARF (collaborate of ARF) was induced by oncogenic RasV12. The expression of CARF was up-regulated in both HCC mouse model (Alb-Cre; P53f/f; Loxp-Stop-Loxp-RasG12D) and human HCC clinical samples. Overexpression of CARF promoted the growth and migration of HCC cells, while knocking down the expression of CARF inhibited the growth and migration of HCC cells. In the mechanism study, CARF was found to interact with beta-catenin, impaired the interaction between beta-catenin and ICAT, and activated beta-catenin/TCF signaling. Moreover, knocking down the expression of CARF inhibited the tumorigenesis in the HCC mouse model. Taken together, this study revealed the oncogenic functions of CARF in the tumorigenesis of HCC by activating beta-catenin/TCF signaling, and suggested CARF might be a therapeutic target in the treatment of HCC.
Insights
Collaborator of ARF (CARF) promotes hepatocellular carcinoma (HCC) growth by activating beta-catenin signaling. Targeting CARF may offer new therapeutic strategies for HCC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling
Background:
- Ras signaling pathway overactivation is common in hepatocellular carcinoma (HCC).
- Targeting Ras directly is challenging, necessitating identification of downstream effectors.
- CARF (collaborator of ARF) was investigated as a potential Ras effector in HCC.
Purpose of the Study:
- To investigate the role of CARF in HCC tumorigenesis.
- To elucidate the mechanism by which CARF influences HCC progression.
- To evaluate CARF as a potential therapeutic target for HCC.
Main Methods:
- Utilized a genetically engineered mouse model (Alb-Cre; P53f/f; Loxp-Stop-Loxp-RasG12D) of HCC.
- Analyzed CARF expression in HCC mouse models and human HCC samples.
- Performed gain-of-function and loss-of-function studies on HCC cells (overexpression and knockdown of CARF).
- Investigated CARF's interaction with beta-catenin and its effect on beta-catenin/TCF signaling.
Main Results:
- CARF expression is induced by oncogenic RasV12 and upregulated in HCC.
- CARF overexpression promotes HCC cell growth and migration.
- CARF knockdown inhibits HCC cell growth, migration, and tumorigenesis.
- CARF interacts with beta-catenin, disrupts beta-catenin/ICAT interaction, and activates beta-catenin/TCF signaling.
Conclusions:
- CARF functions as an oncogene in HCC tumorigenesis.
- CARF promotes HCC by activating beta-catenin/TCF signaling.
- CARF represents a potential therapeutic target for HCC treatment.
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic...
Canonical Wnt Signaling Pathway
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
MAPK Signaling Cascades
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Master Transcription Regulators

